Pfizer Inc. (NYSE:PFE) Stock Holdings Lowered by TIAA Trust National Association

TIAA Trust National Association lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 405,240 shares of the biopharmaceutical company's stock after selling 41,107 shares during the period. TIAA Trust National Association's holdings in Pfizer were worth $10,751,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PFE. Modern Wealth Management LLC grew its position in Pfizer by 48.7% during the fourth quarter. Modern Wealth Management LLC now owns 42,336 shares of the biopharmaceutical company's stock valued at $1,095,000 after acquiring an additional 13,865 shares during the period. Segall Bryant & Hamill LLC lifted its stake in shares of Pfizer by 4.3% in the 4th quarter. Segall Bryant & Hamill LLC now owns 76,539 shares of the biopharmaceutical company's stock valued at $2,031,000 after purchasing an additional 3,177 shares in the last quarter. CoreFirst Bank & Trust purchased a new stake in shares of Pfizer during the 4th quarter worth about $226,000. Barnett & Company Inc. increased its position in Pfizer by 4.3% during the 4th quarter. Barnett & Company Inc. now owns 222,898 shares of the biopharmaceutical company's stock worth $5,913,000 after purchasing an additional 9,273 shares in the last quarter. Finally, Prudential Financial Inc. raised its holdings in Pfizer by 67.5% in the fourth quarter. Prudential Financial Inc. now owns 6,927,537 shares of the biopharmaceutical company's stock valued at $183,788,000 after buying an additional 2,792,786 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Finally, Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company's stock.

Pfizer Stock Up 0.3 %

NYSE PFE traded up $0.08 during trading hours on Friday, reaching $25.09. 16,447,532 shares of the company traded hands, compared to its average volume of 38,981,863. The stock has a market capitalization of $142.27 billion, a PE ratio of 17.79, a PEG ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a 50 day moving average of $26.09 and a two-hundred day moving average of $26.97.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the firm earned $0.10 earnings per share. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.